{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:15:56Z","timestamp":1790500556568,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,2,27]],"date-time":"2014-02-27T00:00:00Z","timestamp":1393459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.jaci.2014.02.007","type":"journal-article","created":{"date-parts":[[2014,3,27]],"date-time":"2014-03-27T02:45:53Z","timestamp":1395888353000},"page":"560-567.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":201,"title":["Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab"],"prefix":"10.1016","volume":"134","author":[{"given":"Aidan","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelkader","family":"Rahmaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Rothman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Guinan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Eisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary S.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Iribarren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillis","family":"Carrigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Ros\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley J.","family":"Szefler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2014.02.007_bib1","unstructured":"Novartis US, Genentech. Omalizumab (Xolair) prescribing information. July 2010. Available at: http:\/\/www.gene.com\/download\/pdf\/xolair_prescribing.pdf. Accessed February 26, 2014."},{"key":"10.1016\/j.jaci.2014.02.007_bib2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"Soler","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2014.02.007_bib3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2014.02.007_bib4","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","article-title":"Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma","volume":"34","author":"Holgate","year":"2004","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2014.02.007_bib5","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1398-9995.2004.00770.x","article-title":"The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma","volume":"60","author":"Bousquet","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2014.02.007_bib6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2014.02.007_bib7","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.rmed.2008.06.002","article-title":"Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study","volume":"102","author":"Niven","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2014.02.007_bib8","first-page":"A359","article-title":"Clinical data do not suggest a causal relationship between omalizumab therapy and cancer [abstract]","volume":"2","author":"Fernandez","year":"2005","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.jaci.2014.02.007_bib9","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1081-1206(10)60184-6","article-title":"Baseline characteristics of patients enrolled in EXCELS: a cohort study","volume":"103","author":"Long","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"suppl\u00a055","key":"10.1016\/j.jaci.2014.02.007_bib10","first-page":"719s","article-title":"Omalizumab and malignancy: interim results from the EXCELS study [abstract]","volume":"38","author":"Eisner","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2014.02.007_bib11","first-page":"A4492","article-title":"Omalizumab and the incidence of malignancy: interim results from the EXCELS study [abstract]","volume":"183","author":"Long","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2014.02.007_bib12","unstructured":"Eisner M, Miller M, Chou W, Rahmaoui A, Bradley M, Ros\u00e9n K. Omalizumab and the incidence of malignancy in patients with moderate or severe asthma: interim results from the EXCELS study. Poster presented at: European Academy of Allergy and Clinical Immunology Congress; June 16-20, 2012; Geneva, Switzerland."},{"key":"10.1016\/j.jaci.2014.02.007_bib13","unstructured":"National Cancer Institute. Surveillance Epidemiology and End Results (SEER). Available at: http:\/\/seer.cancer.gov\/. Accessed February 26, 2014."},{"key":"10.1016\/j.jaci.2014.02.007_bib14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1398-9995.2010.02522.x","article-title":"Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma","volume":"66","author":"Bousquet","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2014.02.007_bib15","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2014.02.007_bib16","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.jaci.2012.01.033","article-title":"Omalizumab and the risk of malignancy: results from a pooled analysis","volume":"129","author":"Busse","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2014.02.007_bib17","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1183\/09031936.93.06050694","article-title":"Cancer risk in asthmatic subjects selected from hospital discharge registry","volume":"6","author":"Kallen","year":"1993","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2014.02.007_bib18","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ijc.21883","article-title":"Atopic diseases, immunoglobulin E and risk of cancer of the prostate, breast, lung and colorectum","volume":"119","author":"Wang","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jaci.2014.02.007_bib19","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1093\/ije\/22.6.976","article-title":"Cancer incidence among 78,000 asthmatic patients","volume":"22","author":"Vesterinen","year":"1993","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jaci.2014.02.007_bib20","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1398-9995.1995.tb01212.x","article-title":"A prospective study of cancer incidence in a cohort examined for allergy","volume":"50","author":"Eriksson","year":"1995","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2014.02.007_bib21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/oxfordjournals.aje.a116494","article-title":"Allergy and cancer: organ site-specific results from the Adventist Health Study","volume":"136","author":"Mills","year":"1992","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jaci.2014.02.007_bib22","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.bjc.6604890","article-title":"Cancer risk in hospitalised asthma patients","volume":"100","author":"Ji","year":"2009","journal-title":"Br J Cancer"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674914002048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674914002048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T08:48:53Z","timestamp":1758790133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674914002048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0091674914002048"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2014.02.007","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2014.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}